


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+5.41%
+0.27%
+0.81%
+3.85%
IOVA
Iovance Biotherapeutics
$2.50
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
Chart
$2.19 (+14.16%)
$2.23 (+12.11%)
$1.75 (+42.86%)
$9.03 (-72.31%)
IOVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Price under $5

High volatilty

IOVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
IOVA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
IOVA Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is IOVA current stock price?
What are IOVA stock strengths?
What is IOVA Risk Level?
What is IOVA market cap and volume?
What is IOVA current Stock IQ?
Should I buy IOVA stock right now?
Is IOVA a Strong Buy right now?
What does a 'Strong Buy' rating mean for IOVA?
What does a 'Strong Sell' rating mean for IOVA?
What factors influence IOVA's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+5.41%
+0.27%
+0.81%
+3.85%
IOVA
Iovance Biotherapeutics
Current Price
$2.50
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Chart
$2.19 (+14.16%)
$2.23 (+12.11%)
$1.75 (+42.86%)
$9.03 (-72.31%)
IOVA Analysts Opinion
IOVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
IOVA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
IOVA Street Sentiment is extremely bullish and have positive views on the near-term outlook
IOVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Price under $5

High volatilty

Average key support and resistance price levels.
IOVA Latest Analysis
Down 75% in 12 Months Can Iovance Biotherapeutics Stock Turn Things Around?. Key PointsIovance obtained approval for Amtagvi last year which has given its top line a big boost.
Tue Nov 11, 2025
Chardan Capital Maintains Iovance Biotherapeutics (IOVA) Buy Recommendation. Fintel reports that on November 6 2025 Chardan Capital maintained coverage of Iovance Biotherapeutics (NasdaqGM:IOVA) with a Buy recommendation. Analyst Price Forecast Suggests 301.82% Upside
Fri Nov 7, 2025
2 Small-Cap Stocks With Far More Upside Than Any &.Magnificent Seven&. Stock According to Wall Street. Key PointsIovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs.
Fri Nov 7, 2025
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3 Revenues Up Y/Y. Iovances shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
Fri Nov 7, 2025
Iovance rises 34% as Q3 bottom line beat supported by strong Amtagvi sales.
Thu Nov 6, 2025
Iovance Biotherapeutics reports mixed Q3 results. reaffirms FY25 outlook.
Thu Nov 6, 2025
Iovance Biotherapeutics Highlights Business Achievements Pipeline Milestones and Third Quarter 2025 Results. Quarterly Revenue Growth of 13% to ~$68 Million
Thu Nov 6, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
IOVA Stock trends
IOVA Stock performance
IOVA Stock analysis
IOVA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.